Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors

Moertel CG et al. (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227–232

Modlin IM et al. (2006) The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab 91: 2340–2348

Rindi G et al. (2007) Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 18: 145–149

Ferrone CR et al. (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25: 5609–5615

Van Eeden S et al. (2002) Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol 33: 1126–1132

Rindi G et al. (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451: 757–762

Schurr P et al. (2007) Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 245: 273–281

Touzios JG et al. (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241: 776–783

Sarmiento JM et al. (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197: 29–37

Chamberlain RS et al. (2000) Hepatic neuroendocrine metastases: does intervention affect outcome? J Am Coll Surg 190: 432–445

Ruszniewski P et al. (1993) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71: 2624–2630

Eriksson BK et al. (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83: 2293–2301

Gupta S et al. (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer 9: 261–267

Moertel C et al. (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120: 302–309

Bloomston M et al. (2007) Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg 11: 264–271

Lamberts SW et al. (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323: 1246–1249

Cwikla JB et al. (2007) Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin—single NET center experience in Poland. Neuro Endocrinol Lett 28: 789–800

Dromain C et al. (2005) Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23: 70–78

Kumbasar B et al. (2004) Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging 29: 696–702

Asnacios A et al. (2008) Indium-111–pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 26: 963–970

Reichlin S (1983) Somatostatin. N Engl J Med 309: 1495–1501

Reubi JC et al. (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50: 5969–5977

Kvols LK et al. (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315: 663–666

Di Bartolomeo M et al. (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77: 402–408

Ruszniewski P et al. (1996) Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39: 279–283

Faiss S et al. (1996) Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res 142: 193–207

Welin SV et al. (2004) High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 151: 107–112

Arnold R et al. (1993) Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 54: 72–75

Saltz L et al. (1993) Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72: 244–248

Ducreux M et al. (2000) The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95: 3276–3281

Panzuto F et al. (2006) Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17: 461–466

Moertel CG et al. (1989) Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7: 865–888

Saltz L et al. (1994) A phase II trial of α-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 74: 958–961

Plöckinger U and Wiedenmann B (2007) Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 21: 145–162

Faiss S et al. (2003) Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689–2696

Välimäki M et al. (1991) Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 67: 547–549

Vavra JJ et al. (1960) Streptozotocin, a new antibacterial antibiotic. Antibiot Annu 1: 230–235

Murray-Lyon IM et al. (1968) Treatment of multiple-hormone-producing malignant islet-cell tumor with streptozocin. Lancet 2: 895–898

Schein PS et al. (1974) Clinical antitumour acitivity and toxicity of streptozotocin (NSC-85998). Cancer 34: 993–1000

Schein P et al. (1973) Streptozocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature. Arch Intern Med 132: 555–561

Moertel CG et al. (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303: 1189–1194

Moertel CG et al. (1992) Streptozocin–doxorubicin, streptozocin–fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519–523

Cheng PN and Saltz LB (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86: 944–948

Rivera E and Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21: 36–38

Kouvaraki MA et al. (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22: 4762–4771

Gonzalez MA et al. (2003) Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 89: 455–456

Moertel CG and Hanley JA (1979) Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2: 327–334

Engstrom PF et al. (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2: 1255–1259

Bukowski RM et al. (1987) A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60: 2891–2895

Sun W et al. (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23: 4897–4904

Ramanathan RK et al. (2001) Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group–E6282. Ann Oncol 12: 1139–1143

Bukowski RM et al. (1994) Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group Study. Cancer 73: 1505–1508

Kulke MH et al. (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24: 401–406

Varker KA et al. (2008) Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 61: 661–668

Ekeblad S et al. (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13: 2986–2991

Kulke MH et al. (2007) Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET) [abstract #4505]. ASCO Meeting Abstracts 25: 4505

Waldherr C et al. (2001) The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12: 941–945

Waldherr C et al. (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 43: 610–616

Virgolini I et al. (2002) 111In- and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. J Nucl Med 32: 148–155

Valkema R et al. (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36: 147–156

Kwekkeboom DJ et al. (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26: 2124–2130

Kwekkeboom DJ et al. (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic tumors. J Clin Oncol 23: 2754–2762

Duran I et al. (2006) A phase II clinical and pharmacodynamic study trial of temsirolimus in advanced neuroendocrine tumors. Br J Cancer 95: 1148–1154

Yao JC et al. (2007) Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET) [abstract #4503]. ASCO Meeting Abstracts 25: 4503

Terris B et al. (1998) Expression of vascular endothelial growth factor in digestive tumours. Histopathology 32: 133–138

Phan AT et al. (2006) Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma [abstract #4091]. ASCO Meeting Abstracts 24: 4091

Yao JC et al. (2005) Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract #4007]. 2005 ASCO Meeting Abstracts 23: 4007

Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

Sandler A et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542–2550

Miller KD et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792–799

Miller K et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676

Kulke MH et al. (2006) A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors [abstract #4044]. ASCO Meeting Abstracts 24: 4044

Kulke M et al. (2005) Results of a phase II study with sunitinib malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs) [abstract #718]. Eur J Cancer Suppl 3: 204

Nilsson O et al. (1992) Presence of IGF-1 in human midgut carcinoid tumours—an autocrine regulator of carcinoid tumour growth? Int J Cancer 51: 195–203

Adams TE et al. (2000) Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57: 1050–1093

Wang Y and Sun Y (2002) Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2: 191–207

Pollak MN et al. (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505–518

Ouban A et al. (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34: 803–808

García-Echeverría C et al. (2004) In vivo antitumor activity of NVP-AEW541—a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231–239